Nurix Therapeutics, Inc. has amended its agreement with Piper Sandler to offer up to $413.65 million in common stock through 'at the market' offerings, as reported on March 6, 2026. This follows previous amendments and a universal automatic shelf registration statement filed on July 11, 2024.